ES520637A0 - Metodo de preparar compuestos carbostirilicos. - Google Patents

Metodo de preparar compuestos carbostirilicos.

Info

Publication number
ES520637A0
ES520637A0 ES520637A ES520637A ES520637A0 ES 520637 A0 ES520637 A0 ES 520637A0 ES 520637 A ES520637 A ES 520637A ES 520637 A ES520637 A ES 520637A ES 520637 A0 ES520637 A0 ES 520637A0
Authority
ES
Spain
Prior art keywords
carbostirilic
preparing
compounds
preparing carbostirilic
carbostirilic compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
ES520637A
Other languages
English (en)
Other versions
ES8403885A1 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of ES8403885A1 publication Critical patent/ES8403885A1/es
Publication of ES520637A0 publication Critical patent/ES520637A0/es
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/40—Nitrogen atoms attached in position 8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
ES520637A 1980-10-31 1983-03-15 Metodo de preparar compuestos carbostirilicos. Granted ES520637A0 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP55154071A JPS5777676A (en) 1980-10-31 1980-10-31 Carbostyril derivative

Publications (2)

Publication Number Publication Date
ES8403885A1 ES8403885A1 (es) 1984-04-16
ES520637A0 true ES520637A0 (es) 1984-04-16

Family

ID=15576252

Family Applications (3)

Application Number Title Priority Date Filing Date
ES507198A Granted ES507198A0 (es) 1980-10-31 1981-10-29 Procedimiento de preparar compuesto carbostiribicos.
ES520637A Granted ES520637A0 (es) 1980-10-31 1983-03-15 Metodo de preparar compuestos carbostirilicos.
ES520638A Expired ES8403886A1 (es) 1980-10-31 1983-03-15 Procedimiento de preparar compuestos carbostirilicos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES507198A Granted ES507198A0 (es) 1980-10-31 1981-10-29 Procedimiento de preparar compuesto carbostiribicos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES520638A Expired ES8403886A1 (es) 1980-10-31 1983-03-15 Procedimiento de preparar compuestos carbostirilicos.

Country Status (24)

Country Link
US (1) US4415572A (es)
JP (1) JPS5777676A (es)
KR (1) KR860001944B1 (es)
AR (2) AR242563A1 (es)
AT (1) AT381701B (es)
AU (1) AU524419B2 (es)
BE (1) BE890942A (es)
CA (1) CA1209575A (es)
CH (2) CH650782A5 (es)
DE (2) DE3153260C2 (es)
DK (1) DK155665C (es)
ES (3) ES507198A0 (es)
FI (1) FI77450C (es)
FR (2) FR2493320B1 (es)
GB (1) GB2086896B (es)
IT (2) IT1210585B (es)
MX (1) MX8481A (es)
NL (2) NL194205C (es)
NO (1) NO158099C (es)
PH (1) PH17962A (es)
PT (1) PT73910B (es)
SE (2) SE448877B (es)
SU (1) SU1426452A3 (es)
ZA (1) ZA817515B (es)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5883677A (ja) * 1981-11-11 1983-05-19 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体
JPS5929667A (ja) * 1982-08-13 1984-02-16 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体および強心剤
CH655110A5 (de) * 1982-09-03 1986-03-27 Otsuka Pharma Co Ltd Carbostyrilderivate, verfahren zu deren herstellung und arzneimittel, welche diese enthalten.
US4730000A (en) * 1984-04-09 1988-03-08 Abbott Laboratories Quinoline antibacterial compounds
NZ209876A (en) * 1983-10-17 1988-03-30 Duphar Int Res Piperazines and pharmaceutical compositions
JPS60126270A (ja) * 1983-12-14 1985-07-05 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体
PT79699B (en) * 1983-12-22 1986-12-10 Pfizer Process for preparing quinolone inotropic agents
US4774246A (en) * 1984-01-26 1988-09-27 Abbott Laboratories Quinoline antibacterial compounds
GR851296B (es) * 1984-05-29 1985-11-25 Pfizer
JPS60256133A (ja) * 1984-06-01 1985-12-17 Fuji Photo Film Co Ltd 放射線画像情報記録読取装置
DE3582371D1 (de) * 1984-07-06 1991-05-08 Otsuka Pharma Co Ltd Oxindolverbindungen, diese enthaltende zusammensetzungen sowie verfahren zur herstellung derselben.
US4760064A (en) * 1984-12-18 1988-07-26 Otsuka Pharmaceutical Co., Ltd. Carbostyril compounds, compositions containing same and processes for preparing same
JPH07100696B2 (ja) * 1984-12-18 1995-11-01 大塚製薬株式会社 カルボスチリル誘導体
JPS61145162A (ja) * 1984-12-19 1986-07-02 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体
EP0185429A1 (en) * 1984-12-21 1986-06-25 Duphar International Research B.V New bicyclic heteroaryl piperazines
DE3586794T2 (de) * 1984-12-21 1993-05-27 Duphar Int Res Arzneimittel mit psychotroper wirkung.
US4845100A (en) * 1985-04-12 1989-07-04 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and salts thereof, processes for preparing the same and cardiotonic composition containing the same
DE3524067A1 (de) * 1985-07-05 1987-01-08 Boehringer Mannheim Gmbh Neue benzimidazole, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel sowie zwischenprodukte
US4666913A (en) * 1985-11-22 1987-05-19 William H. Rorer, Inc. Hydroxy and aminothiazolyl-benzodiazinone compounds, cardiotonic compositions including the same, and their uses
GB8529362D0 (en) * 1985-11-28 1986-01-02 Pfizer Ltd Quinolone cardiac stimulants
JPH0625123B2 (ja) * 1985-12-12 1994-04-06 大塚製薬株式会社 カルボスチリル誘導体−シクロデキストリン包接化合物
US4689325A (en) * 1985-12-23 1987-08-25 Abbott Laboratories Isoxazolo-pyrido-phenoxazine and isothiazolo-pyrido-phenoxazine derivatives
US4687770A (en) * 1985-12-23 1987-08-18 Abbott Laboratories Isoxazolo-pyrido-benzoxazine and isothiazolo-pyrido-benzoxazine derivatives
US5358949A (en) * 1986-03-05 1994-10-25 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and salts thereof and anti-arrhythmic agents containing the carbostyril derivatives
DK111387A (da) * 1986-03-05 1987-09-06 Otsuka Pharma Co Ltd Carbostyrilderivater og salte deraf, laegemiddel indeholdende saadanne derivater samt fremgangsmaade til fremstilling af derivaterne
GB8630702D0 (en) * 1986-12-23 1987-02-04 Wellcome Found Quinoline compound
US5166160A (en) * 1986-12-23 1992-11-24 Burroughs Wellcome Co. Quinoline compound
JPS63225357A (ja) * 1987-03-12 1988-09-20 Otsuka Pharmaceut Co Ltd カルボスチリル誘導体
GB8827189D0 (en) * 1988-11-21 1988-12-29 Fujisawa Pharmaceutical Co 2(1h)-quinolinone compounds processes for preparation thereof & pharmaceutical composition comprising same
DE69230131T2 (de) * 1991-07-03 2000-03-02 Otsuka Pharmaceutical Co., Ltd. Apoptoseregulator
US5750529A (en) * 1991-07-03 1998-05-12 Otsuka Pharmaceutical Co., Ltd. Apoptosis regulating compostion
WO1993011769A1 (fr) * 1991-12-10 1993-06-24 Otsuka Pharmaceutical Co., Ltd Agent anticancereux
JP2686887B2 (ja) * 1992-08-11 1997-12-08 キッセイ薬品工業株式会社 ピペリジノ−３，４−ジヒドロカルボスチリル誘導体
CA2121148A1 (en) * 1992-08-19 1994-03-03 Otsuka Pharmaceutical Co., Ltd. Apoptosis regulator
JP2826790B2 (ja) * 1992-12-26 1998-11-18 キッセイ薬品工業株式会社 ３，４−ジヒドロカルボスチリル誘導体
US5521185A (en) * 1993-03-02 1996-05-28 Otsuka Pharmaceutical Co., Ltd. Methods for inhibiting graft rejection and IL-1 production
JPH0733664A (ja) * 1993-07-26 1995-02-03 Otsuka Pharmaceut Co Ltd 平滑筋細胞増殖抑制剤
GB9326232D0 (en) * 1993-12-23 1994-02-23 Zeneca Ltd Chemical compounds
GB9326373D0 (en) * 1993-12-23 1994-02-23 Zeneca Ltd Chemical compounds
US5504093A (en) * 1994-08-01 1996-04-02 Otsuka Pharmaceutical Co., Ltd. Method for inhibiting nucleoside and nucleobase transport in mammalian cells, and method for inhibition of DNA virus replication
ES2271967T3 (es) 1996-03-29 2007-04-16 Duphar International Research B.V Compuestos de piperazina y piperidina.
GB2312843A (en) * 1996-05-07 1997-11-12 Merck & Co Inc Method of treating rheumatoid arthritis
US5684007A (en) * 1996-09-05 1997-11-04 Otsuka Pharmaceutical Co., Ltd. Methods for inhibiting cardiac fibroblast growth and cardiac fibrosis
MXPA02002032A (es) 1999-08-27 2003-05-19 Ligand Pharm Inc Compuestos moduladores del receptor de androgeno y metodos.
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
EP1212322A2 (en) 1999-08-27 2002-06-12 Ligand Pharmaceuticals Incorporated 8-substituted-6-trifluoromethyl-9-pyrido[3,2-g]quinoline compounds as androgen receptor modulators
EP1216221A2 (en) 1999-09-14 2002-06-26 Ligand Pharmaceuticals Incorporated Rxr modulators with improved pharmacologic profile
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
AU2004266160A1 (en) * 2003-08-22 2005-03-03 Ligand Pharmaceuticals Incorporated 6-cycloamino-2-quinolinone derivatives as androgen receptor modulator compounds
US20080171746A1 (en) * 2005-03-14 2008-07-17 Thomas Klein Method for Preventing Cardiovascular Diseases
KR101289995B1 (ko) 2005-09-27 2013-07-26 시오노기 앤드 컴파니, 리미티드 Ｐｇｄ2 수용체 길항제 활성을 갖는 설폰아마이드 유도체
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EA201391254A1 (ru) 2011-03-01 2014-02-28 Синерджи Фармасьютикалз Инк. Способ получения агонистов гуанилатциклазы c
JP6499591B2 (ja) 2013-02-25 2019-04-10 シナジー ファーマシューティカルズ インコーポレイテッド 結腸洗浄において用いるためのグアニル酸シクラーゼ受容体アゴニスト
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
WO2014151200A2 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
CN105764916B (zh) 2013-06-05 2021-05-18 博士医疗爱尔兰有限公司 鸟苷酸环化酶c的超纯激动剂、制备和使用所述激动剂的方法
EP3492106B1 (en) 2013-08-09 2021-02-17 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
EP3972599B1 (en) 2019-05-21 2025-10-22 Ardelyx, Inc. Combination for lowering serum phosphate in a patient

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1278385B (de) * 1965-03-30 1968-09-26 Bayer Ag Aufhellungsmittel
GB1299172A (en) * 1968-10-15 1972-12-06 Lilly Industries Ltd Heterocyclic anti-inflammatory agents
DE2719562C2 (de) * 1976-05-08 1986-05-07 Otsuka Pharmaceutical Co. Ltd., Tokio/Tokyo 3, 4-Dihydrocarbostyrilderivate, Verfahren zu deren Herstellung und Arzneimittel, welche diese enthalten
JPS54130589A (en) * 1978-03-31 1979-10-09 Yoshitomi Pharmaceut Ind Ltd Pyridazine derivative and its preparation
JPS54135785A (en) * 1978-04-12 1979-10-22 Yoshitomi Pharmaceut Ind Ltd Pyridazinone derivative and its preparation
JPS54138585A (en) * 1978-04-18 1979-10-27 Yoshitomi Pharmaceut Ind Ltd Pyridazine derivative and its preparation
JPS54141785A (en) * 1978-04-26 1979-11-05 Yoshitomi Pharmaceut Ind Ltd Preparation of carboxylic acid derivative
JPS6017072B2 (ja) * 1978-09-05 1985-04-30 三菱電機株式会社 赤熱金属検出器
JPS5549319A (en) * 1978-10-06 1980-04-09 Yoshitomi Pharmaceut Ind Ltd Remedy for suppression of blood platelet-agglutination
JPS5553283A (en) * 1978-10-12 1980-04-18 Yoshitomi Pharmaceut Ind Ltd Pyridazinone derivative
JPS5576872A (en) * 1978-12-06 1980-06-10 Yoshitomi Pharmaceut Ind Ltd Imidazolidinone derivative
JPS5583781A (en) * 1978-12-19 1980-06-24 Yoshitomi Pharmaceut Ind Ltd Pyridazinone derivative

Also Published As

Publication number Publication date
IT1210585B (it) 1989-09-14
PH17962A (en) 1985-02-20
SE8106430L (sv) 1982-05-01
DE3142982A1 (de) 1982-06-24
SE8406209L (sv) 1984-12-06
SE466655B (sv) 1992-03-16
DE3142982C2 (de) 1985-12-19
FI77450B (fi) 1988-11-30
FR2493320B1 (fr) 1985-08-23
IT8149588A0 (it) 1981-10-29
SE448877B (sv) 1987-03-23
KR860001944B1 (ko) 1986-11-01
MX8481A (es) 1994-02-28
NO158099C (no) 1988-07-13
US4415572A (en) 1983-11-15
ATA460281A (de) 1986-04-15
DK480381A (da) 1982-05-01
SU1426452A3 (ru) 1988-09-23
KR830007607A (ko) 1983-11-04
DE3153260A1 (es) 1985-05-15
SE8406209D0 (sv) 1984-12-06
JPS5777676A (en) 1982-05-15
ES520638A0 (es) 1984-04-16
ES8403885A1 (es) 1984-04-16
IT8547867A0 (it) 1985-03-26
CH656616A5 (de) 1986-07-15
AU524419B2 (en) 1982-09-16
BE890942A (fr) 1982-02-15
CH650782A5 (de) 1985-08-15
AR242375A1 (es) 1993-03-31
FR2552760A1 (fr) 1985-04-05
DE3153260C2 (es) 1989-05-24
AR242563A1 (es) 1993-04-30
ZA817515B (en) 1982-10-27
NL194205C (nl) 2001-09-04
AT381701B (de) 1986-11-25
FR2552760B1 (fr) 1988-08-05
GB2086896A (en) 1982-05-19
FI813408L (fi) 1982-05-01
ES8306743A1 (es) 1983-06-16
AU7699681A (en) 1982-05-06
NO158099B (no) 1988-04-05
NL8403096A (nl) 1985-02-01
JPH0143747B2 (es) 1989-09-22
PT73910B (en) 1983-04-18
DK155665C (da) 1989-09-04
NL194205B (nl) 2001-05-01
FI77450C (fi) 1989-03-10
ES8403886A1 (es) 1984-04-16
PT73910A (en) 1981-11-01
CA1209575A (en) 1986-08-12
DK155665B (da) 1989-05-01
IT1226479B (it) 1991-01-16
FR2493320A1 (fr) 1982-05-07
NO813678L (no) 1982-05-03
ES507198A0 (es) 1983-06-16
NL8104923A (nl) 1982-05-17
GB2086896B (en) 1984-10-10

Similar Documents

Publication Publication Date Title
ES520637A0 (es) Metodo de preparar compuestos carbostirilicos.
ES516523A0 (es) "metodo de preparar compuestos benzoheterociclicos".
ES507545A0 (es) Procedimiento de preparar compuestos carbostirilicos.
FI810505A7 (fi) Menetelmä 3-jodimetyylikefalosporiinien valmistamiseksi.
FI820518A7 (fi) Menetelmä substituoitujen 3-amino- sydnonimiinien valmistamiseksi.
KR850003303A (ko) 치환된 벤조일-우레아의 제조방법
ES520029A0 (es) Metodo de producir ferrosilicio.
FI822408A7 (fi) Menetelmä amidobentsamidien valmistamiseksi.
FI810778A7 (fi) Menetelmä pyrimidinyylikinatsoliinien valmistamiseksi.
FI813666A7 (fi) Menetelmä 3,4-bis-substituoitujen 1,2,5- oksdiatsoli-2-oksidien valmistamiseksi.
FI793221A7 (fi) Menetelmä substituoitujen pyrrolidiestereiden valmistamiseksi.
FI793444A7 (fi) Menetelmä uusien aryylitrifluorietanolien valmistamiseksi.
FI810935A7 (fi) Menetelmä substituoitujen triaryylitiatsoliyhdisteiden valmistamiseksi.
FI811546A7 (fi) Menetelmä 3-pikoliinin valmistamiseksi.
FI810658A7 (fi) Menetelmä 1-kromaanin N- imidatsolyyliderivaattien valmistamiseksi.
FI792449A7 (fi) Menetelmä uusien tiosubstituoitujen diatsasykloalkeenien valmistamiseksi.
ES521596A0 (es) Metodo de preparar compuestos piridotienopiridacinicos.
FI822647A7 (fi) 4-amino-butyramidin valmistusmenetelmä.
FI812518A7 (fi) Menetelmä uusien polyatsaheterosyklisten yhdisteiden valmistamiseksi.
FI812779A7 (fi) Menetelmä 1-oksa- -laktami antibioottien valmistamiseen.
FI800481A7 (fi) Menetelmä substituoitujen asyylipiperiidiinien valmistamiseksi.
FI814067A7 (fi) Uusien laktaamiyhdisteiden valmistusmenetelmä.
FI813391A7 (fi) 2-halogeeni-3- sulfonyyliakryylinitriilien valmistusmentelmä.
ES502653A0 (es) Metodo de preparacion de ftalimidoguanidinas
ES512697A0 (es) "metodo de preparar compuestos metilquinoxalin-1,4-dioxidicos".

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 20040202